Jeffrey X Duggan

发表

Detection of cynomolgus monkey anti-protein XYZ antibody using immunocapture-LC/MS

S. Norris, Jeffrey X. Duggan, Lin-Zhi Chen, 2016 .

Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.

W. Guo, I. Ahmad, Ateeq Ahmad, 2005, Journal of chromatography. A.

Progress in high-sensitivity hybrid LC-MS/MS methods for the bioanalysis of protein drugs and performance tests for their validation.

Jeffrey X. Duggan, Jeffrey X Duggan, 2018, Bioanalysis.

Quantification of raf antisense oligonucleotide (rafAON) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulation.

W. Guo, I. Ahmad, Ateeq Ahmad, 2005, Biomedical chromatography : BMC.

2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines 'Scientific'? (Part 1 - LCMS: small molecules, peptides and small molecule biomarkers).

Sam H Haidar, Olivier Le Blaye, Gustavo Mendes Lima Santos, 2017, Bioanalysis.

Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics

Surinder Kaur, Jianing Zeng, Faye Vazvaei, 2014, The AAPS Journal.

Quantification below the LLOQ in regulated LC-MS/MS assays: a review of bioanalytical considerations and cautions.

Jeffrey X. Duggan, Jeffrey X Duggan, 2019, Bioanalysis.

LC-MS quantification of protein drugs: validating protein LC-MS methods with predigestion immunocapture.

Jeffrey X. Duggan, Lin-Zhi Chen, Jeffrey X Duggan, 2016, Bioanalysis.

Bioanalytical method validation considerations for LC-MS/MS assays of therapeutic proteins.

F. Vazvaei, Jeffrey X. Duggan, Jeffrey X Duggan, 2015, Bioanalysis.

2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies' inputs).

Hao Jiang, Amanda Wilson, Eric Woolf, 2017, Bioanalysis.